DoMore Diagnostics

Executive Summary

DoMore Diagnostics is a Norwegian digital pathology company founded in 2016, dedicated to developing AI-based diagnostic solutions for cancer. Its lead product, Histotype Px® Colorectal, analyzes digitized tumor tissue images to predict outcomes and chemotherapy benefit in colon cancer patients, aiming to reduce over- and undertreatment. The company has raised undisclosed funding and is positioned in the rapidly growing AI diagnostics market. While still in early commercial stages, its technology addresses a significant clinical need for personalized treatment planning in colorectal cancer, a high-incidence disease. Recent validation studies and potential regulatory milestones could drive near-term value.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval (FDA or CE marking) for Histotype Px® Colorectal60% success
• Q2 2026Publication of pivotal clinical validation study results70% success
• Q4 2026Strategic partnership with a major diagnostics or pharmaceutical company50% success